Treatment Approach for Prostate Cancer with High-Risk Features

Risk Classification and Assessment

The American College of Physicians and the National Comprehensive Cancer Network recommend that patients with high-risk prostate cancer, such as those with Gleason 4+3 and extensive involvement of biopsy cores (12/18), be considered for aggressive treatment approaches 1, 2
The Gleason score 4+3 is associated with a poorer prognosis compared to 3+4 due to the predominant pattern of 4, which indicates worse differentiation 1, 3
The National Comprehensive Cancer Network guidelines suggest that the extensive involvement of biopsy cores (12/18) is an unfavorable risk factor that shifts patients toward the higher risk category 2

The National Comprehensive Cancer Network recommends radical prostatectomy with pelvic lymph node dissection as a primary treatment option for high-risk prostate cancer patients with life expectancy ≥5 years, especially when external beam radiation therapy is not preferred 1, 5
Alternative treatment options for high-risk prostate cancer include external beam radiation therapy with 2-3 years of androgen deprivation therapy, or external beam radiation therapy plus brachytherapy with or without androgen deprivation therapy, as recommended by the National Comprehensive Cancer Network 5

The National Comprehensive Cancer Network guidelines indicate that radical prostatectomy provides excellent cancer control for patients with intermediate to high-risk disease when the disease is organ-confined 6
Radical prostatectomy allows for precise pathological staging and identification of adverse features that may guide adjuvant therapy decisions, according to the National Comprehensive Cancer Network 6

The National Comprehensive Cancer Network recommends considering adjuvant therapy if adverse pathological features are found after surgery, such as positive margins, seminal vesicle invasion, or extracapsular extension 6
Options for adjuvant therapy include observation with early salvage radiation, adjuvant radiation therapy, or adjuvant androgen deprivation therapy with or without radiation therapy, as suggested by the American College of Physicians and the National Comprehensive Cancer Network 1, 6

A low Decipher score suggests a lower genomic risk of metastasis, which may influence decisions about adjuvant therapy after surgery, according to the National Comprehensive Cancer Network guidelines 4, 5
Despite a low Decipher score, high-volume disease (12/18 cores) and Gleason 4+3 pattern warrant definitive treatment rather than observation or active surveillance, as recommended by the National Comprehensive Cancer Network 2, 5

After radical prostatectomy, serum PSA should fall below detection level within 2 months, and regular PSA monitoring is essential to detect early biochemical recurrence, as suggested by the National Comprehensive Cancer Network guidelines 4